“The GLP-1 agonist market is seeing unprecedented growth, and we’re investing €900 million to capture a fair amount of that business,” says CordenPharma’s Dr Mimoun Ayoub, outlining the CDMO’s most ambitious expansion plan to date in response to surging demand
Corden Pharma has announced its largest strategic investment to date with a committed spend of approximately €900 million over the next three years to grow its Peptide technology platform. This ambitious expansion involves major initiatives in the US and Europe,
CordenPharma, a global CDMO specialising in the manufacture of Drug Substances (APIs) for complex modalities, and Certest, a Spanish company focused on developing new products in Drug Delivery, have announced a partnership agreement. The collaboration is set to add ionizable
Stay ahead of trends and best practices
Exclusive downloads and podcasts
Get invites to special events and meetups 
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
